This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study
comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88
stable patients with a research diagnosis of schizophrenia determined with the Structured
Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness
duration (i.e., 5 years) in order to allow for post-hoc analyses examining
whether earlier illness moderates greater negative and /or cognitive symptom reduction in
response to vortioxetine.